MRK vs BMY
By Alex · Tickerpine
Merck & Co., Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | BMY |
|---|---|---|
| Price | $128.66 | $57.52 |
| Market cap | $317.77B | $117.46B |
| P/E ratio | 36.2 | 16.1 |
| ROE | 18.94% | 38.73% |
| Profit margin | 13.59% | 15.01% |
| Revenue growth | 4.90% | 2.60% |
| Dividend yield | 2.64% | 4.38% |
| Beta | 0.22 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs BMY in plain English
- MRK is the bigger company — about 2.7× the market cap of BMY.
- BMY is cheaper on earnings (P/E 16.1 vs 36.2).
- BMY earns a higher return on equity (39% vs 19%).
- MRK is growing revenue faster (5% vs 3%).
- BMY has the higher dividend yield (4.38% vs 2.64%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.